Oncology & Hematology Coding Alert

Reader Question:

96413 Usually Pairs With J1745

Question: We provide infusion services for patients being treated with Remicade. Should we use chemotherapy or other therapy administration codes?Colorado SubscriberAnswer: Payers are free to determine which non-chemotherapy agents they pair with chemotherapy administration codes, which reflect a higher level of skill and therefore a higher fee than non-chemo admin codes. You're likely to find that payers instruct you to report Remicade infusions using chemotherapy infusion codes, such as 96413 (Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug) and +96415 (Chemotherapy administration, intravenous infusion technique; each additional hour [List separately in addition to code for primary procedure]).Colorado MAC TrailBlazer offers a Chemotherapy job aid that states "Chemotherapy administration codes apply to parenteral administration of ... substances such as monoclonal antibody agents." It goes on to state infliximab is "commonly considered to fall under the category of monoclonal antibodies" (www.trailblazerhealth.com/Publications/Job%20Aid/ChemotherapyAdministrationPartB.pdf).  This content is taken from [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in your eNewsletter
  • 6 annual AAPC-approved CEUs*
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more
*CEUs available with select eNewsletters.

Other Articles in this issue of

Oncology & Hematology Coding Alert

View All